Roberts Glore & CO Inc Neurocrine Biosciences Inc Transaction History
Roberts Glore & CO Inc
- $328 Million
- Q2 2024
A detailed history of Roberts Glore & CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Roberts Glore & CO Inc holds 1,492 shares of NBIX stock, worth $187,260. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,492
Previous 1,492
-0.0%
Holding current value
$187,260
Previous $205,000
-0.0%
% of portfolio
0.06%
Previous 0.06%
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
625Shares Held
94.7MCall Options Held
642KPut Options Held
288K-
Black Rock Inc. New York, NY14.2MShares$1.78 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.25 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.61MShares$578 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$323 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.9MShares$238 Million4.37% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...